Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Daniel da Motta Girardi, Scot Anthony Niglio, Amir Mortazavi, Primo Lara, Sumanta K. Pal, Biren Saraiya, Lisa M. Cordes, Lisa Ley, Olena Sierra Ortiz, Jacqueline Cadena, Carlos Diaz, Mohammadhadi H. Bagheri, Seth M. Steinberg, Rene Costello, Howard Streicher, John Wright, Howard L. Parnes, Yang-Min Ning, Donald P. Bottaro, Andrea B. Apolo
Institutions: National Institutes of Health, National Cancer Institute, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Wexner Medical Center, University of California System, City Of Hope National Medical Center, Rutgers Cancer Institute, National Institutes of Health Clinical Center, United States Food and Drug Administration, Center for Cancer Research
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W3029944933